{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:28:56Z","timestamp":1787956136757,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":700,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/jto.0000000000000011","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T11:31:05Z","timestamp":1387279865000},"page":"83-90","source":"Crossref","is-referenced-by-count":29,"title":["Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Vera","family":"Hirsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy K.","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray D.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Renschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0000000000000011_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1078-5337(02)00089-8","article-title":"The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer","volume":"9","author":"Socinski","year":"2003","journal-title":"Respir Care Clin N Am"},{"key":"10.1097\/JTO.0000000000000011_bib3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"10.1097\/JTO.0000000000000011_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0000000000000011_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.317.7161.771","article-title":"Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews","volume":"317","author":"Silvestri","year":"1998","journal-title":"BMJ"},{"key":"10.1097\/JTO.0000000000000011_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/082585970702300303","article-title":"Self-perceived burden to others: patient and family caregiver correlates","volume":"23","author":"McPherson","year":"2007","journal-title":"J Palliat Care"},{"key":"10.1097\/JTO.0000000000000011_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.socscimed.2006.09.013","article-title":"Feeling like a burden: exploring the perspectives of patients at the end of life","volume":"64","author":"McPherson","year":"2007","journal-title":"Soc Sci Med"},{"key":"10.1097\/JTO.0000000000000011_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.NJH.0000289656.91880.f2","article-title":"Patients' experiences of being a burden on family in terminal illness","volume":"9","author":"Johnson","year":"2007","journal-title":"J Hosp Palliat Nurs"},{"key":"10.1097\/JTO.0000000000000011_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JTO.0b013e31815e8b48","article-title":"Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer","volume":"3","author":"de Marinis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib10","first-page":"557","article-title":"Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer","volume":"9","author":"Mohan","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1097\/JTO.0000000000000011_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/JTO.0b013e31815cff64","article-title":"A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer","volume":"2","author":"Tanvetyanon","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib12","author":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology"},{"key":"10.1097\/JTO.0000000000000011_bib13","series-title":"Taxol (paclitaxel) [package insert]","year":"2011"},{"key":"10.1097\/JTO.0000000000000011_bib14","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib15","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0000000000000011_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0000000000000011_bib17","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1200\/JCO.2007.10.8605","article-title":"Phase I\/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer","volume":"26","author":"Rizvi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e3181d5e39e","article-title":"A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer","volume":"5","author":"Socinski","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","article-title":"Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer","volume":"26","author":"Belani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.lungcan.2011.12.001","article-title":"A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer","volume":"76","author":"Gao","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000011_bib24","series-title":"Abraxane for Injectable Suspension (paclitaxel particles for injectable suspension) (albumin-bound) [package insert]","year":"2012"},{"key":"10.1097\/JTO.0000000000000011_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF01218365","article-title":"The use of the Calvert formula to determine the optimal carboplatin dosage","volume":"121","author":"van Warmerdam","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0000000000000011_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JOP.0854601","article-title":"Good clinical practice research guidelines reviewed, emphasis given to responsibilities of investigators: second article in a series","volume":"4","year":"2008","journal-title":"J Oncol Pract"},{"key":"10.1097\/JTO.0000000000000011_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clbc.2012.05.001","article-title":"Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival","volume":"12","author":"Gradishar","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1097\/JTO.0000000000000011_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment","volume":"90","author":"Pachman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"10.1097\/JTO.0000000000000011_bib30","first-page":"107","article-title":"Neurotoxicity of Taxol","author":"Rowinsky","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1097\/JTO.0000000000000011_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.23321","article-title":"Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer","volume":"112","author":"Rivera","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1097\/JTO.0000000000000011_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6349(10)70002-1","article-title":"Nanoparticle albumin-bound (nab)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer","volume":"8","author":"Cortes","year":"2010","journal-title":"EJC Supplements"},{"key":"10.1097\/JTO.0000000000000011_bib33","series-title":"Bristol-Myers Squibb Company","year":"2004"},{"key":"10.1097\/JTO.0000000000000011_bib34","series-title":"Taxotere (docetaxel) [package insert]","year":"2010"},{"key":"10.1097\/JTO.0000000000000011_bib35","first-page":"239","article-title":"Paraclinical evaluation of side-effects of taxanes on auditory system","volume":"28","author":"Sarafraz","year":"2008","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"suppl 1","key":"10.1097\/JTO.0000000000000011_bib36","doi-asserted-by":"crossref","first-page":"eS46","DOI":"10.3949\/ccjm.78.s2.10","article-title":"Selection of chemotherapy for patients with advanced non-small cell lung cancer","volume":"79","author":"Pennell","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"10.1097\/JTO.0000000000000011_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5306\/wjco.v2.i6.262","article-title":"Review of the treatment of metastatic non small cell lung carcinoma: a practical approach","volume":"2","author":"Hirsh","year":"2011","journal-title":"World J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415301660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415301660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T07:27:01Z","timestamp":1597217221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415301660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1556086415301660"],"URL":"https:\/\/doi.org\/10.1097\/jto.0000000000000011","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}